查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1772195

癌症基因治療市場規模、佔有率、趨勢分析報告：按適應症、載體類型、給藥途徑、地區和細分市場預測，2025-2030 年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

癌症基因治療市場的成長與趨勢：

根據Grand View Research的最新報告，到2030年全球癌症基因治療市場規模預計將達到127.6億美元。

由於全球對新型治療藥物的需求不斷成長以及全球癌症發病率的上升，預計該市場在2025年至2030年間的複合年成長率將達到19.34%。此外，該治療方法為各種遺傳性和誘發性癌症提供了絕對的解決方案，使其成為更理想的癌症治療選擇。例如，Kite公司的Tecartus（brexucabtagene autoleucel）已獲得FDA核准，用於治療復發或難治性B細胞前驅急性淋巴細胞白血病。

全球惡性腫瘤的發生率不斷上升，預計這將推動對有效治療方案和各種策略的需求，以應對惡性腫瘤日益成長的發病率。此外，市場技術進步預計將為新型療法帶來新的機會。因此，核准的產品數量正在增加。例如，2022年3月，歐洲藥品管理局建議有條件地核准Carvykti（ciltacabtagene autoleucel）用於治療復發和難治性多發性骨髓瘤。

世界各國政府和國家癌症協會的大力支持正積極推動市場發展。人們越來越重視增加癌症基因治療的研究經費。例如，2021年12月，一個名為DARE-NL（荷蘭）的荷蘭平台獲得了KWF荷蘭癌症協會520萬美元的津貼。這筆津貼將使DARE-NL能夠提升細胞和基因治療策略，使弱勢族群能夠獲得更便利的治療方案。

亞洲製造商對新型複雜技術的投資較少，因為他們專注於可以大量生產的簡單分子，而歐洲和北美等其他已開發地區的製造商則投資高產量、低成本的技術，以避免競爭壓力。

市場上的主要參與者正致力於合作開發強效的癌症基因治療藥物。例如，2022年8月，Gensaic與Ovid Therapeutics簽署了一項合作協議，利用該公司專有的噬菌體衍生顆粒基因治療平台，開發最多三種用於中樞神經系統疾病的基因藥物。

癌症基因治療市場報告重點

  • 隨著我們對基因層面癌症病理學的理解不斷進步，以及對基因導向免疫療法和個人化醫療的需求不斷增加，市場正在發生重大變化。
  • 由於基因誘導免疫治療研究的進展，基因誘導免疫治療領域將在2024年佔據最大佔有率。
  • 對新型基因療法的需求不斷成長以及 FDA 對癌症基因療法核准數量的不斷增加，使得生物製藥公司在 2024 年佔據了最大的市場佔有率。由於該領域研發活動的增加，預計生物製藥公司在預測期內將呈現最快的成長速度。
  • 由於主要企業的存在以及政府和國家癌症研究所為促進該地區癌症研究而加強的支持力度，北美在 2024 年佔據了市場主導地位。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章癌症基因治療市場：適應症業務分析

  • 指示細分儀表板
  • 全球癌症基因治療市場趨勢及波動分析
  • 全球癌症基因治療市場規模及趨勢分析（依適應症，2018-2030）
  • 大B細胞淋巴瘤
  • 多發性骨髓瘤
  • 急性淋巴性白血病（ALL）
  • 黑色素瘤（病變）
  • 其他

第5章癌症基因治療市場：給藥途徑業務分析

  • 給藥途徑細分儀表板
  • 全球癌症基因治療市場給藥途徑變化分析
  • 全球癌症基因治療市場規模及趨勢分析（依給藥途徑，2018-2030）
  • 靜脈
  • 其他

第6章癌症基因治療市場：載體類型的商業分析

  • 向量類型細分儀表板
  • 全球癌症基因治療市場中基於載體的變異分析
  • 全球癌症基因治療市場規模及趨勢分析（依載體類型，2018-2030年）
  • 慢病毒
  • 逆轉錄病毒和γ逆轉錄病毒
  • AAV
  • 改良單純皰疹病毒
  • 腺病毒
  • 其他

第7章 癌症基因治療市場：依適應症、給藥途徑和載體類型進行的區域估計和趨勢分析

  • 區域儀表板
  • 2018年至2030年市場規模、預測與趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 瑞士
  • 亞太地區
    • 日本
    • 中國
    • 韓國
  • 世界其他地區

第8章 競爭態勢

  • 參與企業
  • 戰略地圖
  • 2024年企業市場分析
  • 參與企業概況
    • Amgen Inc.
    • Novartis AG
    • Gilead Sciences, Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company
    • Legend Biotech.
    • Nanjing IASO Biotechnology
    • JW Therapeutics
    • CARsgen Therapeutics
    • Krystal Biotech, Inc.
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.34% from 2025 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine.
  • The gene induced immunotherapy segment held the largest share in 2024 due to increase in the advancement in gene induced immunotherapy research.
  • Biopharmaceutical companies held the largest market share in 2024 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field.
  • North America dominated the market in 2024 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Indication
    • 1.2.2. Route of Administration
    • 1.2.3. Vector Type
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Advancements in gene therapy technology
      • 3.2.1.3. Increasing adopton of personalized medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High costs of treatment
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gene Therapy Market: Indication Business Analysis

  • 4.1. Indication Segment Dashboard
  • 4.2. Global Cancer Gene Therapy Market Indication, Movement Analysis
  • 4.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Large B-Cell Lymphoma
    • 4.4.1. Global Large B-Cell Lymphoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Multiple Myeloma
    • 4.5.1. Global Multiple Myeloma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Acute Lymphoblastic Leukemia (ALL)
    • 4.6.1. Global Acute Lymphoblastic Leukemia (ALL) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Melanoma (lesions)
    • 4.7.1. Global Melanoma (lesions) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Global Cancer Gene Therapy Market Route of Administration Movement Analysis
  • 5.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Global Intravenous Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: VectorType Business Analysis

  • 6.1. Vector Type Segment Dashboard
  • 6.2. Global Cancer Gene Therapy Market Vector Type Movement Analysis
  • 6.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Vector Type, 2018 to 2030 (USD Million)
  • 6.4. Lentivirus
    • 6.4.1. Global Lentivirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. RetroVirus & gamma RetroVirus
    • 6.5.1. Global RetroVirus & gamma RetroVirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. AAV
    • 6.6.1. Global AAV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Modified Herpes Simplex Virus
    • 6.7.1. Global Modified Herpes Simplex Virus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Adenovirus
    • 6.8.1. Global Adenovirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Indication, Route of Administration, & Vector Type

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Switzerland
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. South Korea
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. South Korea Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Rest of the World
    • 7.6.1. Rest of the World Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Participant's Overview
    • 8.4.1. Amgen Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. bluebird bio, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Legend Biotech.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Nanjing IASO Biotechnology
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. JW Therapeutics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. CARsgen Therapeutics
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Krystal Biotech, Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 4 Global cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 6 Global cancer gene therapy market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 9 North America cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 11 U.S. cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 12 U.S. cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 14 Canada cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Canada cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 17 Mexico cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Mexico cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 20 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Europe cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 24 UK cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 25 UK cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 UK cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 27 Germany cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Germany cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Germany cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 30 Switzerland cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Switzerland cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Switzerland cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 37 Japan cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Japan cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 40 China cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 41 China cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 42 China cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 43 South Korea cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 44 South Korea cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 South Korea cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 46 Rest of the world cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Rest of the world cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Rest of the world cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 49 Participant's overview
  • Table 50 Financial performance
  • Table 51 Key companies undergoing expansions
  • Table 52 Key companies undergoing acquisitions
  • Table 53 Key companies undergoing collaborations
  • Table 54 Key companies launching new products
  • Table 55 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Cancer gene therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Cancer gene therapy market driver analysis
  • Fig. 12 Cancer gene therapy market restraint analysis
  • Fig. 13 Cancer gene therapy market: Porter's analysis
  • Fig. 14 Cancer gene therapy market: PESTEL analysis
  • Fig. 15 Cancer gene therapy market: Indication outlook and key takeaways
  • Fig. 16 Cancer gene therapy market: Indication market share analysis, 2024 - 2030
  • Fig. 17 Global cancer gene therapy by large B-cell lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 18 Global cancer gene therapy by multiple myeloma market, 2018 - 2030 (USD Million)
  • Fig. 19 Global cancer gene therapy by Acute Lymphoblastic Leukemia (ALL) market, 2018 - 2030 (USD Million)
  • Fig. 20 Global cancer gene therapy by melanoma (lesions) market, 2018 - 2030 (USD Million)
  • Fig. 21 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer gene therapy market: Route of administration outlook and key takeaways
  • Fig. 23 Cancer gene therapy market: Route of administration market share analysis, 2024 - 2030
  • Fig. 24 Global cancer gene therapy by intravenous market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 26 Cancer gene therapy market: Vector type outlook and key takeaways
  • Fig. 27 Cancer gene therapy market: Vector type market share analysis, 2024 - 2030
  • Fig. 28 Global cancer gene therapy by lentivirus market, 2018 - 2030 (USD Million)
  • Fig. 29 Global cancer gene therapy by retrovirus & gamma retrovirus market, 2018 - 2030 (USD Million)
  • Fig. 30 Global cancer gene therapy by AAV market, 2018 - 2030 (USD Million)
  • Fig. 31 Global cancer gene therapy by modified herpes simplex virus market, 2018 - 2030 (USD Million)
  • Fig. 32 Global cancer gene therapy by adenovirus market, 2018 - 2030 (USD Million)
  • Fig. 33 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Canada cancer gene therapy market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Europe cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 UK cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Germany cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Switzerland cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Asia-Pacific cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Japan cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 China cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Rest of the world cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key company categorization
  • Fig. 49 Company market positioning
  • Fig. 50 Market participant categorization
  • Fig. 51 Strategy framework